title: Mouse skin graft prolongation with donor strain bone marrow and anti-lymphocyte serum: surface markers of the active bone marrow cells.
abstract: The survival of C3H/HeJ skin grafts on B6AF1 mice treated with anti-lymphocyte serum (ALS) can be significantly prolonged by the injection of the host with C3H/HeJ bone marrow. Although the prolongation is apparently due at least in part to the ultimate presence in the host of specific suppressor cells of donor origin, little is known about the nature of the cells in the marrow inoculum that are responsible for this effect. The present investigation was undertaken to characterize surface markers of the active bone marrow cells. Marker-positive populations were either depleted and enriched by panning techniques or depleted by killing with specific antibody and complement, and then were assayed for their ability to prolong graft survival. Cells that were adherent to anti-Ia-coated plates extended graft survival only slightly better than did treatment with ALS alone, whereas nonadherent (Ia-depleted) cells, as well as cells treated with anti Ia and complement, retained good prolonging activity. Similarly, panning on anti-immunoglobulin (Ig)-coated plates produced an active, Ig+-depleted population and an inactive adherent population, and killing of Thy-1+ cells with antibody and complement did not compromise the ability of the bone marrow inoculum to prolong graft survival. Complement receptor-positive (EAC+) and Fc gamma receptor-positive cells (EA+) were separated by panning on plates coated with sheep erythrocytes/antibody/complement and erythrocytes/7S antibody respectively. Adherent, EAC+-enriched cells were only slightly active, whereas the nonadherent, EAC-depleted population was fully active in graft prolongation. However, both Fc gamma R+ (EA+)-enriched and depleted populations were active, with the enriched fraction producing significantly better prolongation than the depleted population. Thus, the bone marrow cells that can prolong skin graft survival in ALS-treated mice appear to be Ia-, Thy-1+, largely complement receptor negative, and Ig-, but are largely positive for Fc gamma receptors.
authors.forename: S
authors.initials: S
authors.lastname: De Fazio
authors.forename: W C
authors.initials: WC
authors.lastname: Hartner
authors.forename: A P
authors.initials: AP
authors.lastname: Monaco
authors.forename: J J
authors.initials: JJ
authors.lastname: Gozzo
mesh_terms: D000818:Animals; D000954:Antigens, Surface / Q000032:analysis; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D001853:Bone Marrow / Q000276:immunology; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D002469:Cell Separation / Q000379:methods; D006082:Graft Enhancement, Immunologic / Q000379:methods*; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D010641:Phenotype; D011946:Receptors, Antigen / Q000032:analysis*; D011947:Receptors, Antigen, B-Cell / Q000032:analysis; D011951:Receptors, Complement / Q000032:analysis; D011961:Receptors, Fc / Q000032:analysis; D017452:Receptors, IgG; D016038:Skin Transplantation; D018800:Thy-1 Antigens
chemical_list: D000954:Antigens, Surface; D000961:Antilymphocyte Serum; D000949:Histocompatibility Antigens Class II; D011946:Receptors, Antigen; D011947:Receptors, Antigen, B-Cell; D011951:Receptors, Complement; D011961:Receptors, Fc; D017452:Receptors, IgG; D018800:Thy-1 Antigens